Corticosteroid-Induced Osteoporosis
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 24 (8) , 607-624
Abstract
Corticosteroid-induced osteoporosis is a major cause of morbidity and is the leading secondary cause of osteoporosis today. Unfortunately, despite this knowledge, patients receiving corticosteroid therapy are often not offered any preventative treatment. Recent research has focused attention on the critical role the osteoblast has played in the pathophysiology of corticosteroid-induced osteoporosis. In addition to an initial increase in bone resorption, there is evidence that corticosteroids induce osteoblast and osteocyte apoptosis and as a result are important contributors to bone loss. Interesting work has suggested that the bisphosphonates and calcitonin may help to prevent osteoblast apoptosis from occurring. Large scale randomised controlled trials have also been completed with a variety of therapeutic agents. Of the many different therapies, it is now clear that the bisphosphonates have the greatest evidence to support their use. Increases in bone mineral density when compared with a control group, not only at the spine but also at the hip, have been demonstrated. These studies have shown clinically significant reductions in vertebral fracture rates seen for the most part in postmenopausal women. Other therapies may well be effective, as evidenced by maintenance of bone mass in the spine; however, maintenance of bone mass in the hip and reductions in fracture rate have yet to be demonstrated for many of these therapies. Given our current knowledge and the evidence that is outlined in this review, it is hoped that patients who require therapy with corticosteroids for more than 3 months will be offered appropriate preventative treatment.Keywords
This publication has 165 references indexed in Scilit:
- Prevention of corticosteroid-induced osteoporosis: Results of a patient surveyArthritis & Rheumatism, 1999
- Current and potential future drug treatments for osteoporosis.Annals of the Rheumatic Diseases, 1996
- The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: A study of postmenopausal twinsJournal of Bone and Mineral Research, 1996
- Tamoxifen protects against steroid-induced bone lossEuropean Journal of Cancer, 1992
- Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cellsJournal of Bone and Mineral Research, 1992
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Glucocorticoid-Induced OsteoporosisNew England Journal of Medicine, 1983
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983
- The intestinal handling of calcium by the rat in vivo, as affected by cortisol. Effect of dietary calcium supplementsCalcified Tissue International, 1978
- Effect of cortisone treatment on the active transport of calcium by the small intestineJournal of Clinical Investigation, 1971